At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 58 enrolled
Drug / intervention
exenatidedrug
Likely dose
exenatide 5mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes
In Brief
A Phase 3 clinical trial evaluating exenatide for Type 2 Diabetes Mellitus. Completed, enrolled 58 participants across 13 sites in 5 countries.
Detailed Summary
The primary purpose of this study is to assess the anti-exenatide-antibody response to exenatide re-exposure as measured by anti-exenatide antibodies and incidence of treatment-emergent allergy and hypersensitivity reactions following a period of treatment interruption, in patients previously exposed to exenatide.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesAustralia, Canada, Hungary, Italy, South Korea
CollaboratorsEli Lilly and Company
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedAug 2007
Primary CompletionApr 2008
TodayJul 2026
First PostedAug 14, 2007
Enrollment StartAug 1, 2007
Primary CompletionApr 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.9 years ago
Interventions
exenatidedrug
subcutaneous injection, 5mcg or 10mcg, twice a day